Zhaoke Ophthalmology Limited reported Q4 2025 results characterized by a substantial gross loss and a continued, material R&D-driven burn against a relatively modest revenue base. Revenue for Q4 2025 was 15.90 million CNY, while cost of revenue stood at 34.83 million CNY, producing a gross loss of 18.92 million CNY and a negative gross margin of -119.0%. Operating expenses were 94.09 million CNY, with selling, general and administrative expenses totaling 53.96 million CNY, culminating in an EBITDA of -88.54 million CNY and an operating income of -113.01 million CNY. Net income for the quarter was -90.82 million CNY (EPS -0.16). The balance sheet remains cash-rich, with cash and cash equivalents of 1,296.30 million CNY and total debt of 292.48 million CNY, yielding a net debt of -1,003.81 million CNY (net cash). The company’s liquidity position is strong, with current assets of ~1,374.43 million CNY and current liabilities of ~328.55 million CNY (current ratio ~4.19x). R&D expenditure was substantial at 40.12 million CNY, underscoring a heavy emphasis on pipeline development ahead of near-term revenue realization. The quarter sits in the context of an R&D-intensive development phase typical for ophthalmology biotechs, where profitability is often suppressed until regulatory milestones or licensing transactions materialize. Given the lack of disclosed formal forward guidance, the investment thesis centers on pipeline progression, potential collaborations or license deals, and sustained liquidity to fund clinical readouts over the next several quarters. Overall, the QQ4 2025 results reflect a development-stage profile with strong balance-sheet flexibility but a need for near-term catalysts to unlock profitability.